Author:
Vice President - Bioinformatics : Chandra Sekhar Pedamallu
Prinicipal Scientific Manager: Debasis Pore
Senior Scientific Manager II: Katyayni Vinnakota
Senior Technical Program Manager I: Harrisham Kaur, Meeta Sunil, Priyanka Shah,Priyanka Shah, Harrisham Kaur
Senior Scientific Manager I: Amrita Bhattacherjee, Govardhan Kothapalli Shroff
Technical Program Manager II: Hita Garapati
Technical Program Manager I: Nag Himakund Mallampalli, Praveen Korepu
Scientific Manager I: Mahendra Pal Singh, Snehal Dilip Karpe, Neha Kulkarni, Anjali Kumari, Aditya Mahadevan Iyer
Senior Scientific Specialist I: Shikha Roy, Tuhina Srivastava, Harshmi Shah, Ankush Jadhav
Senior Scientific Analyst II: Shylander Raju Tumiki
Group Head: Jitesh K. Pillai (Program Management), Puneet Saxena (Computational Biology), Uzma Saeed (Biology)
Introduction:
Biomarkers are indicators of homeostasis, disease states, or pharmacological interventions. An ideal biomarker must be binary (present or absent), quantifiable in tissues, cells, body fluids, or in simple physiological parameters such as blood sugar or blood pressure with minimal variability, should have substantial signal to noise ratio (sensitive and specific), and vary promptly and reliably in response to changes due to an underlying condition or treatment. The main benefits and limitations of biomarkers are summarized.
Also referred to as biological markers, molecular markers, surrogate endpoints, or signature molecules, biomarkers are of immense significance to biopharma, diagnostics, personalized medicine, and overall healthcare industry. The global biomarkers market valued at USD 66.97 billion in 2022 is expected to grow at a CAGR of 13.3% from 2023 to 2030. Variables such as enhanced impact of companion diagnostics, rise in incidence and prevalence of cancers, cardiovascular, neurological, and immunological diseases, higher private and public investments and funding, noteworthy inventions from current R&D, and novel digital health technology solutions are expected to disrupt and catapult the growth of the biomarker industry.
Biomarkers have a wide spectrum of functionalities, ranging from early drug discovery, to pre-clinical, and finally late-stage clinical development as depicted.
For more information click download PDF of the White Paper.
Connect with Excelra experts: marketing@excelra.com
www.excelra.com
